Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buchler

Showing results (451-460 of 502) with videos related to

Pageof 51
Sort By:
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 16, 2015
Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrationsN Pallet, A-S Jannot, M El Bahri, et al.
Scientific Reports|December 21, 2025
Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumabOndřej Fiala, Katarína Rejleková, Tomas Buchler, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2017
A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative DisordersSophie Caillard, Etienne Cellot, Jacques Dantal, et al.
British Journal of Cancer|June 2, 2026
Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors studyMichal Mego, Edgar Israelyan, Robert J Hamilton, et al.
Cancer Letters|April 18, 2016
Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumorsL Boublikova, V Bakardjieva-Mihaylova, K Skvarova Kramarzova, et al.
International Journal of Cancer|December 31, 2024
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trialViktor Grünwald, Rana R McKay, Tomas Buchler, et al.
Transplantation|February 26, 2019
Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM StudyHelio Tedesco-Silva, Julio Pascual, Ondrej Viklicky, et al.
Kidney International|December 26, 2022
Machine learning does not outperform traditional statistical modelling for kidney allograft failure predictionAgathe Truchot, Marc Raynaud, Nassim Kamar, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Pageof 51

Showing results (451-460 of 502) with videos related to

Sort By:
Pageof 51
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 16, 2015
Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrationsN Pallet, A-S Jannot, M El Bahri, et al.
Scientific Reports|December 21, 2025
Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumabOndřej Fiala, Katarína Rejleková, Tomas Buchler, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2017
A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative DisordersSophie Caillard, Etienne Cellot, Jacques Dantal, et al.
British Journal of Cancer|June 2, 2026
Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors studyMichal Mego, Edgar Israelyan, Robert J Hamilton, et al.
Cancer Letters|April 18, 2016
Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumorsL Boublikova, V Bakardjieva-Mihaylova, K Skvarova Kramarzova, et al.
International Journal of Cancer|December 31, 2024
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trialViktor Grünwald, Rana R McKay, Tomas Buchler, et al.
Transplantation|February 26, 2019
Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM StudyHelio Tedesco-Silva, Julio Pascual, Ondrej Viklicky, et al.
Kidney International|December 26, 2022
Machine learning does not outperform traditional statistical modelling for kidney allograft failure predictionAgathe Truchot, Marc Raynaud, Nassim Kamar, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Pageof 51